BioCryst

BioCryst Pharmaceuticals, Inc., commonly referred to as BioCryst, is an American biotechnology company that develops antiviral therapeutics. The company concentrates on small-molecule and nucleotide-based antiviral drugs and related discovery programs. BioCryst is headquartered in Durham, North Carolina, and trades on the NASDAQ stock market under the ticker BCRX.

Its marketed product is peramivir, sold under the brand Rapivab, an intravenous neuraminidase inhibitor approved by the U.S. Food and Drug Administration in 2014 for treatment of influenza in adults and certain pediatric patients.

In addition to peramivir, BioCryst maintains a pipeline of antiviral candidates, including galidesivir, a broad-spectrum antiviral under development for multiple RNA viruses. The company pursues internal discovery programs complemented by collaborations and licensing agreements to advance candidates through preclinical and clinical development.

As a public company, BioCryst operates globally with its drug development programs and manufacturing capabilities. It engages in collaborations with government agencies and other pharmaceutical firms to extend antiviral research and development and to explore potential commercialization opportunities.